Relay Therapeutics (RLAY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
GlobeNewswire16:05 ET
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
Zacks Dec 6 08:40 ET
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $16
Moomoo NewsDec 5 11:35 ET · Ratings
Leerink Partners Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsDec 5 11:35 ET · Ratings
Relay Therapeutics Price Target Lowered to $18 From $19 at Leerink
Yahoo FinanceDec 5 06:51 ET
Relay Therapeutics Price Target Cut to $18.00/Share From $19.00 by Leerink Partners
Dow JonesDec 5 04:45 ET · Ratings

Comments

Jaguar8

4 hours ago

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-se...

Jaguar8

Dec 4 06:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

31

7

6

Jaguar8

Dec 3 21:21

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and c...

Trytosaveabit

Dec 3 21:04

Update

$Relay Therapeutics (RLAY.US)$ Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
2 MINUTES AGO, 8:01 AM EST
VIA GLOBENEWSWIRE
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocar...

Options Newsman

Oct 2 09:25

Columns Options Market Statistics: Options Popped as Investors Placed Bets Before Nike Revealed Earnings

News Highlights
$Meta Platforms (META.US)$ shares increased 0.70%, with with option volume of 0.37 million, and calls accounted for 58.2% of the volume. The $585 calls expiring October 4 were traded most actively.
Meta Platforms said on Tuesday that the company will expand artificial intelligence investment in Vietnam, including production of its mixed reality Quest 3S headsets in the country from next...

39

2

4

RLAY Relay Therapeutics

Trade Overview

Capital Trend

News

Comments